ReviewUpsala journal of medical sciences2012
Glioblastoma--a moving target.
Review in Upsala journal of medical sciences, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 49 citations in OpenAlex.
- Trial
- Management and survival rates in patients with glioma in China (2004-2010): a retrospective study from a single-institution.Journal of neuro-oncology · 2013Trial
- Monitoring Cerebrospinal Fluid Inflammatory Mediators by Olink Target 48 Cytokine Panel.Methods in molecular biology (Clifton, N.J.) · 2025Article
- A nomogram with Ki-67 in the prediction of postoperative recurrence and death for glioma.Scientific reports · 2024Article
- LINC01138 expresses two novel isoforms and functions as a repressive factor in glioma cells.Heliyon · 2024Article
- Role of the circulatory interleukin-6 in the pathogenesis of gliomas: A systematic review.World journal of methodology · 2022Article
- The polarity protein Par3 coordinates positively self-renewal and negatively invasiveness in glioblastoma.Cell death & disease · 2021Article
- From cells to tissue: How cell scale heterogeneity impacts glioblastoma growth and treatment response.PLoS computational biology · 2020Article
- Deficiency of G9a Inhibits Cell Proliferation and Activates Autophagy via Transcriptionally Regulating c-Myc Expression in Glioblastoma.Frontiers in cell and developmental biology · 2020Article
- Current and Future Trends on Diagnosis and Prognosis of Glioblastoma: From Molecular Biology to Proteomics.Cells · 2019Review
- High-Dose Tanshinone IIA Suppresses Migration and Proliferation While Promoting Apoptosis of Astrocytoma Cells Via Notch-1 Pathway.Neurochemical research · 2018Article
- Paradoxical prognostic impact of TERT promoter mutations in gliomas depends on different histological and genetic backgrounds.CNS neuroscience & therapeutics · 2017Article
- Spatially graded hydrogels for preclinical testing of glioblastoma anticancer therapeutics.MRS communications · 2017Article
- The role of miR-451 in the switching between proliferation and migration in malignant glioma cells: AMPK signaling, mTOR modulation and Rac1 activation required.International journal of oncology · 2017Article
- Analysis of DTI-Derived Tensor Metrics in Differential Diagnosis between Low-grade and High-grade Gliomas.Frontiers in aging neuroscience · 2017Article
- Inhibition of miR-21 in glioma cells using catalytic nucleic acids.Scientific reports · 2016Article
- Differential proteomics analysis of low- and high-grade of astrocytoma using iTRAQ quantification.OncoTargets and therapy · 2016Article
- The Transcription Factor ZNF395 Is Required for the Maximal Hypoxic Induction of Proinflammatory Cytokines in U87-MG Cells.Mediators of inflammation · 2015Article
- Analysis of the cytotoxicity of carbon-based nanoparticles, diamond and graphite, in human glioblastoma and hepatoma cell lines.PloS one · 2015Article
- Platelet-derived growth factor in glioblastoma-driver or biomarker?Upsala journal of medical sciences · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The slow development of effective treatment of glioblastoma is contrasted by the rapidly advancing research on the molecular mechanisms underlying the disease. Amplification and overexpression of receptor tyrosine kinases, particularly EGFR and PDGFRA, are complemented by mutations in the PI3K, RB1, and p53 signaling pathways. In addition to finding effective means to target these pathways, we may take advantage of the recent understanding of the hierarchical structure of tumor cell populations, where the progressive expansion of the tumor relies on a minor subpopulation of glioma stem cells, or glioma-initiating cells. Finding ways to reprogram these cells and block their self-renewal is one of the most important topics for future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.